ISU302 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	3

19. ライソゾーム病

---

臨床試験数 : 899 /  薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02770625 (ClinicalTrials.gov)	September 2011	7/5/2016	Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease	A Multicenter, Open-Label Phase III Study to Evaluate the Safety and Efficacy of ISU302 (Imiglucerase for Injection) in Patients With Type 1 Gaucher Disease	Gaucher Disease, Type 1	Drug: ISU302	ISU Abxis Co., Ltd.	NULL	Completed	2 Years	N/A	All	8	Phase 3	NULL
2	NCT01161914 (ClinicalTrials.gov)	January 2011	11/7/2010	The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease	A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease	Gaucher Disease	Drug: Cerezyme®;Drug: ISU302	ISU Abxis Co., Ltd.	NULL	Withdrawn	2 Years	75 Years	Both	0	Phase 3	NULL
3	NCT01881633 (ClinicalTrials.gov)	October 2010	14/6/2013	A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers	A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers	Gaucher Disease	Drug: ISU302;Drug: Placebo	ISU Abxis Co., Ltd.	NULL	Completed	20 Years	45 Years	Male	24	Phase 1	NULL